Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

End Of The 'March-In' Pricing Petitions?

Executive Summary

KEI vows to continue battle over Bayh-Doyle restrictions after US Commerce Department suggests it may issue regulations to exclude pricing as a basis for requiring companies to license their patents.

Advertisement

Related Content

Building A Wall? The Plan To End “March In” Threat To US Drug Patents
Pharma Legislation: From Pricing To Patents
Reining In “March In”: NIH Rejects Xtandi Petition
Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price
BARR LABS GRANTED NONEXCLUSIVE AZT LICENSE BY NIH

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel